This clinical trial compares indocyanine green (ICG)-guided manual lymphatic drainage (MLD) to traditional MLD for the prevention of late-stage breast cancer related lymphedema (BCRL) in breast cancer patients undergoing axillary node dissection. Lymphedema is the build-up of fluid in the body when the lymph system is damaged or blocked. Many breast cancer patients develop BCRL while receiving treatment for their cancer. At the present, there is no cure for this type of lymphedema; however early detection and prevention can prevent progressing to late-stage BCRL. MLD is a type of manual manipulation of the skin that encourages drainage of all regional lymph nodes, which carries fluid away from the tissues back towards the heart. ICG is a dye that helps visualize lymphatic vessels and anatomy using fluorescent light during surgery. In ICG-guided MLD the images of the lymphatic vessels and anatomy captured during surgery are used to help guide MLD focusing on the individual lymphatic pathways. This may be more effective than traditional MLD for the prevention of late-stage BCRL in breast cancer patients undergoing axillary node dissection.
Additional locations may be listed on ClinicalTrials.gov for NCT06327490.
Locations matching your search criteria
United States
Florida
Gainesville
University of Florida Health Science Center - GainesvilleStatus: Active
Contact: Lisa R. P. Spiguel
Phone: 352-265-0169
PRIMARY OBJECTIVE:
I. To determine the feasibility and compliance of daily manual lymphatic drainage (MLD) to prevent progression of lymphatic dysfunction.
SECONDARY OBJECTIVES:
I. To determine if patients undergoing ICG-guided MLD as compared to patients undergoing traditional MLD demonstrate:
Ia. Reduced relative volume changes of the affected limb;
Ib. Lower rates of increased bioimpedance;
Ic. Lower rates of breast cancer related lymphedema symptoms.
II. To evaluate the impact of BCRL patient-reported outcome measures in both groups.
III. To compare incidence of progression to late stage BCRL.
OUTLINE: Patients undergo ICG lymphatic mapping during standard of care axillary lymph node dissection with or without lymphatic reconstruction and are then randomized to 1 of 2 arms.
ARM 1: Patients watch an educational video on performing MLD and receive images of intraoperative lymphatic mapping on study. Patients then perform MLD along their individual lymphatic pathway over 10-20 minutes once daily (QD), or at least three times a week (TIW) on study.
ARM 2: Patients watch an educational video on performing MLD on study. Patients then perform MLD on the generalized arm draining to all regional nodal basins as demonstrated in the video over 10-20 minutes QD, or at least TIW on study.
Additionally, all patients undergo mammography, ultrasound (US), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) during screening.
During the study intervention, patients are followed up at months 1, 3, 6, 9, 12, 15, 18, 21, and 24.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationUniversity of Florida Health Science Center - Gainesville
Principal InvestigatorLisa R. P. Spiguel